Precision BioSciences Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Precision BioSciences zullen naar verwachting dalen met respectievelijk 22.5% en 43.5% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 40.2% per jaar.

Belangrijke informatie

-43.5%

Groei van de winst

-40.2%

Groei van de winst per aandeel

Biotechs winstgroei	27.1%
Inkomstengroei	-22.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	23 Oct 2024

Recente toekomstige groei-updates

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

Winst- en omzetgroeiprognoses

NasdaqCM:DTIL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	26	-73	17	17	4
12/31/2025	23	-63	-7	-52	5
12/31/2024	60	18	-55	-59	5
6/30/2024	88	16	-66	-65	N/A
3/31/2024	58	-20	-73	-72	N/A
12/31/2023	49	-43	-86	-84	N/A
9/30/2023	52	-49	-100	-98	N/A
6/30/2023	47	-31	-49	-45	N/A
3/31/2023	31	-59	-52	-48	N/A
12/31/2022	25	-73	-49	-46	N/A
9/30/2022	21	-76	-52	-48	N/A
6/30/2022	38	-93	-105	-101	N/A
3/31/2022	102	-40	-113	-108	N/A
12/31/2021	116	-31	-17	-11	N/A
9/30/2021	118	-32	-6	-1	N/A
6/30/2021	101	-47	-4	1	N/A
3/31/2021	34	-101	2	7	N/A
12/31/2020	24	-109	-92	-87	N/A
9/30/2020	22	-106	-104	-94	N/A
6/30/2020	19	-101	-101	-86	N/A
3/31/2020	24	-88	-98	-77	N/A
12/31/2019	22	-93	-96	-71	N/A
9/30/2019	21	-87	-92	-63	N/A
6/30/2019	18	-76	-92	-64	N/A
3/31/2019	15	-69	-77	-57	N/A
12/31/2018	11	-46	-67	-52	N/A
9/30/2018	7	-38	-53	-46	N/A
12/31/2017	6	-21	N/A	-24	N/A
12/31/2016	7	-8	N/A	92	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van DTIL zal naar verwachting de komende 3 jaar dalen ( -43.5% per jaar).

Winst versus markt: De winst van DTIL zal naar verwachting de komende 3 jaar dalen ( -43.5% per jaar).

Hoge groeiwinsten: De winst van DTIL zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van DTIL zal naar verwachting de komende 3 jaar dalen ( -22.5% per jaar).

Hoge groei-inkomsten: De omzet van DTIL zal naar verwachting de komende 3 jaar dalen ( -22.5% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van DTIL naar verwachting over 3 jaar hoog zal zijn

Precision BioSciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 15% to US$2.60

Consensus revenue estimates increase by 47%

Price target decreased by 24% to US$5.07

Consensus revenue estimates increase by 17%, EPS downgraded

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Recent updates

Precision BioSciences, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precision Bio: Another CAR-T Laggard With No Solid Prospects

Precision BioSciences, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$12.50

High number of new directors

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Precision BioSciences, Inc. Announces Shalini Sharp Will Not Seek Re-Election to the Board of Directors